The largest database of trusted experimental protocols

Cd19 magnetic microbeads kit

Manufactured by Miltenyi Biotec
Sourced in Germany

The CD19+ magnetic microbeads kit is a laboratory product designed for the isolation and enrichment of CD19-positive cells from various biological samples. The kit contains superparamagnetic microbeads coated with antibodies specific to the CD19 surface antigen, which is expressed on B cells. This product can be used in standard magnetic cell separation protocols to separate and purify CD19-positive cells for further analysis or downstream applications.

Automatically generated - may contain errors

5 protocols using cd19 magnetic microbeads kit

1

DLBCL Patient Sample Collection

Check if the same lab product or an alternative is used in the 5 most similar protocols
This study was approved by the Medical Ethical Committee of Shandong Provincial Hospital affiliated to Shandong University. The paraffin-embedded archived samples from 50 newly diagnosed DLBCL patients and 20 reactive hyperplasia patients were collected. Samples of patients with reactive hyperplasia were referred as control. Histological diagnoses were established according to the WHO classification [26 ]. Peripheral blood mononuclear cells (PBMCs) from the whole blood of healthy donors were isolated using Ficoll-Hypaque density gradient centrifugation (TBD science, Tianjin, China). Normal peripheral blood CD19+ B cells were purified from freshly isolated PBMCs using CD19+ magnetic microbeads kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were incubated with beads for 15 min at 4 °C while rotating. Purified CD19+ B cells were selected according to the manufacturer’s protocols. The purity of isolated populations was assessed by FACS analysis, and cells with >90% purity were collected. All samples were obtained with informed consent in accordance with the Declaration of Helsinki.
+ Open protocol
+ Expand
2

Isolation and Characterization of CLL Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood samples of 96 de novo patients of CLL were collected at the Department of Hematology in Shandong Provincial Hospital after informed consent as approved by the ethics commission. The leukemic clone proportion in peripheral blood of the enrolled CLL patients was > 90%, which could be represented by peripheral blood mononuclear cells [19 (link)]. All the participants were aged between 29 and 85 years (mean age = 60.29 years, s. d. = 11.45). Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient centrifugation, which was described in previous study [20 (link), 21 (link)]. CD19 + B cells from healthy donors were purified using CD19 + magnetic microbeads kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Clinical characteristics of CLL patients, including age, stage, immunoglobulin mutational status, and cytogenetics (FISH) were recorded.
+ Open protocol
+ Expand
3

DLBCL Lymph Node Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lymph node samples from 60 de novo DLBCL patients and 30 reactive lymphoid hyperplasia patients were collected. Histological diagnoses were established according to the World Health Organization (WHO) classification [19 ]. Normal peripheral blood mononuclear cells (PBMCs) from healthy volunteers were isolated by the Ficoll-Hypaque density gradient centrifugation method (TBD Science, Tianjin, China). Normal B cells were purified from freshly isolated PBMCs using CD19+ magnetic microbeads kit (Miltenyi Biotec, Bergisch Gladbach, Germany) as previously reported [20 (link), 21 (link)]. This study was approved by the Medical Ethical Committee of Shandong Provincial Hospital Affiliated to Shandong University. All samples were obtained with informed consent in accordance with the Declaration of Helsinki.
+ Open protocol
+ Expand
4

Chronic Lymphocytic Leukemia Patient Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols
This study was approved by the Shandong Provincial Hospital Affiliated to Shandong University Medical Ethics Committee with the informed consent of each patient based on the Helsinki Declaration. 51 CLL patients newly diagnosed according to the International Workshop on Chronic Lymphocytic revised criterion were collected from January 2013 to September 2019. All samples were obtained following informed consent. The peripheral blood mononuclear cells of patients were extracted by Ficoll-Hypaque density gradient (TBD Science, Tianjin, China). And normal CD19 + B cells were extracted by CD19 + magnetic microbeads kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the method previously reported [12 (link), 28 (link)].
+ Open protocol
+ Expand
5

DLBCL Patient Profiling and Treatment Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lymph node samples were collected from 100 newly diagnosed DLBCL patients and 20 lymphoid reactive hyperplasia (RHL) patients. The diagnostic criteria were established according to the World Health Organization (WHO) classification 30 (link). Among them, 65 enrolled DLBCL patients received treatment, of which 49 documented the treatment regimens and response (Table S1). Besides, the response was evaluated after every three courses of treatment, mainly based on positron emission tomography/computed tomography (PET/CT) results (Table S1). Peripheral blood mononuclear cells (PBMCs) of healthy donors were isolated by the Ficoll-Hypaque density gradient centrifugation method (TBD Science, Tianjin, China) and naïve CD19+ B-cells were separated by CD19+ magnetic microbeads kit (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of enriched CD19+ B-cells was detected by flow cytometry (FCM) analysis, as previously reported (Figure S1A) 31 (link).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!